Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA. Rossi D, et al. Among authors: vallisa d. Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16. Haematologica. 2015. PMID: 25596266 Free PMC article. Clinical Trial.
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
Silingardi V, Federico M, Cavanna L, Avanzini P, Gobbi PG, Lombardo M, Carotenuto M, Frassoldati A, Pieresca C, Vallisa D, et al. Silingardi V, et al. Among authors: vallisa d. Leuk Lymphoma. 1995 Apr;17(3-4):313-20. doi: 10.3109/10428199509056837. Leuk Lymphoma. 1995. PMID: 8580801 Clinical Trial.
CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Gobbi PG, Pieresca C, Cavanna L, Corbella F, Vallisa D, Federico M, Formisano R, Carotenuto M, Merli F, Callea V, Angrilli F, Silingardi V. Gobbi PG, et al. Among authors: vallisa d. Haematologica. 1996 Nov-Dec;81(6):503-12. Haematologica. 1996. PMID: 9009437 Free article. Clinical Trial.
Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Merli F, Federico M, Avanzini P, Ilariucci F, Stelitano C, Iannitto E, Colombi M, Vallisa D, Santagati G, Picinini L. Merli F, et al. Among authors: vallisa d. Haematologica. 1998 Mar;83(3):217-21. Haematologica. 1998. PMID: 9573675 Free article. Clinical Trial.
Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL).
Longo G, Fiorani C, Sacchi S, Callea V, Lombardo M, Federico M, Stelitano C, Angrilli F, Vallisa D, Gobbi PG, Ilariucci F, Frassoldati A, Petrini M, Silingardi V. Longo G, et al. Among authors: vallisa d. Haematologica. 1999 May;84(5):425-30. Haematologica. 1999. PMID: 10329921 Free article. Clinical Trial.
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G; GISL. Sacchi S, et al. Among authors: vallisa d. Haematologica. 2001 Sep;86(9):951-8. Haematologica. 2001. PMID: 11532623 Free article. Clinical Trial.
134 results